Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial Several PD-(L)1 inhibitors have been approved or are in development for the treatment of NSCLC, showing promising efficacy and tolerable safe...
Although DC-based vaccines may seem promising, there are several serious limitations. The use of autologous DCs for individualized therapy will limit the large-scale production of the vaccine and will be technically demanding. Since culturing techniques will also affect the quality of the vaccines gen...
Based on this, we have summarized the characteristics and clinical features of the several cancer immunoediting phases and proposed a new therapeutic concept based on the theory of cancer immunoediting, i.e., a set of precise clinical therapeutic interventions tailored for different cancer immunoediting...
Cancer immunotherapy drugs: immune checkpoint inhibitors Ipilimumab——The first drug to receive approval by the Food and Drug Administration (FDA) for the treatment of advanced melanoma, blocks the activity of a checkpoint protein known as CTLA4, which is expressed on the surface of activated immune...
Drug repurposing is the application of clinically approved drugs, with characterized pharmacokinetic properties and known side effect profiles, to new indications. The search for effective and durable treatment options for cancer therapy remains an unmet medical need. Drug repurposing has emerged as an ...
" Dr. Curiel said. "We've shown that if you test all your immune therapy just in young mice and young people, you'll never learn how it works in older patients — the ones most at risk for cancer. You might conclude that drugs don't work in aged hosts, when they do. But they ...
Its intended use is for the treatment of metastatic, hormone-refractory prostate cancer. Provenge is custom-made for each patient. First, a patient’s immune cells are collected and exposed to a protein that is found in most prostate cancers, linked to an immune-stimulating substance. Next, ...
Scientists continue to research immunotherapies for lung cancer, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapy. They’re also looking to see if combinations of these drugs will help. The following immunotherapy drugs have been approved for use in advanced non-small-cel...
(TIL) to patients with advanced cancer. Although able to kill tumour targetsin vitro, LAK cells did not prove useful for the treatment of patients with metastatic melanoma and renal cancer. A randomised trial, in which IL-2 was administered alone or with LAK cells, failed to show a ...
Engineered T-cell receptor (TCR) therapy.This treatment removes T cells from your blood and reprograms them in a lab so they can find the cancer more easily. The engineered T cells look for tiny targets on the surface of your cancer cells. ...